After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Ozempic/Wegovy is the first drug ... Here's the full list of drugs: "Last year, we proved that negotiating for lower drug prices works. Now, we plan to build on that record by negotiating for ...
Both Wegovy, Novo’s main obesity offering, and diabetes treatment Ozempic ... in the year ahead. CFRA Research analyst Wan Nurhayati recently reduced his price target on the stock from $122 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results